Involvement of CXCR4 Chemokine Receptor in Metastastic HER2-Positive Esophageal Cancer

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Gros, Stephanie J ^a   Kurschat, Nina ^a   Drenckhan, Astrid ^a   Dohrmann, Thorsten ^a   Forberich, Evelyn ^a   Effenberger, Katharina ^a   Reichelt, Uta ^b   Hoffman, Robert M ^c,d   Pantel, Klaus ^a   Kaifi, Jussuf T ^a   Izbicki, Jakob R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ANTICANCER INC   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLERIXAFOR; TRASTUZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; MICROMETASTASIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BODY WEIGHT; BONE MARROW; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; ESOPHAGEAL NEOPLASMS; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MICE; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RECEPTORS, CXCR4; REPRODUCIBILITY OF RESULTS; TUMOR BURDEN; UP-REGULATION;

EID: 84867634937     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047287     Document Type: Article

References (46)

1. Yarden Y, (2001) The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 (Suppl 4): S3-S8.
2. Zhang D, Salto-Tellez M, Do E, Putti TC, Koay ES, (2003) Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 34: 362-368.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
4. Yu D, Hung MC, (2000) Role of erbB2 in breast cancer chemosensitivity. Bioessays 22: 673-680.
5. al-Kasspooles M, Moore JH, Orringer MB, Beer DG, (1993) Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 54: 213-219.
6. Friess H, Fukuda A, Tang WH, Eichenberger A, Furlan N, et al. (1999) Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg 23: 1010-1018.
7. Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D, (1994) Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut 35: 764-768.
8. Jankowski J, Coghill G, Hopwood D, Wormsley KG, (1992) Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut 33: 1033-1038.
9. Nakamura T, Nekarda H, Hoelscher AH, Bollschweiler E, Harbeck N, et al. (1994) Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 73: 1785-1794.
10. Walch A, Specht K, Bink K, Zitzelsberger H, Braselmann H, et al. (2001) Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Lab Invest 81: 791-801.
11. Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, et al. (2003) c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 57: 1323-1327.
12. Lam KY, Tin L, Ma L, (1998) C-erbB-2 protein expression in oesophageal squamous epithelium from oesophageal squamous cell carcinomas, with special reference to histological grade of carcinoma and pre-invasive lesions. Eur J Surg Oncol 24: 431-435.
13. Suwanagool P, Parichatikanond P, Maeda S, (1993) Expression of c-erbB-2 oncoprotein in primary human tumors: an immunohistochemistry study. Asian Pac J Allergy Immunol 11: 119-122.
14. Reichelt U, Duesedau P, Tsourlakis MC, Quaas A, Link BC, et al. (2007) Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 20: 120-129.
15. Tan M, Yao J, Yu D, (1997) Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 57: 1199-1205.
16. Yarden Y, Sliwkowski MX, (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
17. Yu D, Liu B, Tan M, Li J, Wang SS, et al. (1996) Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 13: 1359-1365.
18. Yu DH, Hung MC, (1991) Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene 6: 1991-1996.
19. Baselga J, (2001) The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 37 (Suppl 4): S16-S22.
20. Leyland-Jones B, (2002) Trastuzumab: hopes and realities. Lancet Oncol 3: 137-144.
21. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, et al. (2004) Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22: 1063-1070.
22. Tuma RS, (2005) Trastuzumab trials steal show at ASCO meeting. J Natl Cancer Inst 97: 870-871.
23. Kollmannsberger C, Pressler H, Mayer F, Kanz L, Bokemeyer C, (1999) Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab. Ann Oncol 10: 1393-1394.
24. Locati LD, Rinaldi G, Bossi P, Dagrada GP, Quattrone P, et al. (2005) Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncol 41: 97-98.
25. Gros SJ, Kurschat N, Dohrmann T, Reichelt U, Dancau AM, et al. (2010) Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma. Mol Cancer Ther 9: 2037-2045.
26. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, et al. (2004) Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6: 459-469.
27. Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, et al. (2005) Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 97: 1840-1847.
28. Proudfoot AE, (2002) Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2: 106-115.
29. Rossi D, Zlotnik A, (2000) The biology of chemokines and their receptors. Annu Rev Immunol 18: 217-242.
30. Liotta LA, (2001) An attractive force in metastasis. Nature 410: 24-25.
31. Muller A, Homey B, Soto H, Ge N, Catron D, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56.
32. Izbicki JR, Passlick B, Hosch SB, Kubuschock B, Schneider C, et al. (1996) Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc Surg 112: 623-630.
33. Izbicki JR, Pantel K, Hosch SB, (2002) Micrometastasis in solid epithelial tumors: impact on surgical oncology. Surgery 131: 1-5.
34. Koenig AM, Prenzel KL, Bogoevski D, Yekebas EF, Bubenheim M, et al. (2009) Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma. Ann Surg Oncol 16: 454-462.
35. Pantel K, Riethmuller G, (1996) Micrometastasis detection and treatment with monoclonal antibodies. Curr Top Microbiol Immunol 213 (Pt 3) (): 1-18.
36. Pantel K, Brakenhoff RH, (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4: 448-456.
37. Gros SJ, Dohrmann T, Peldschus K, Schurr PG, Kaifi JT, (2010) Complementary use of fluorescence and magnetic resonance imaging of metastatic esophageal cancer in a novel orthotopic mouse model. Int J Cancer 126: 2671-2681.
38. Gros SJ, Dohrmann T, Rawnaq T, Kurschat N, Bouvet M, et al. (2010) Orthotopic fluorescent peritoneal carcinomatosis model of esophageal cancer. Anticancer Res 30: 3933-3938.
39. Effenberger KE, Schroeder C, Eulenburg C, Reeh M, Tachezy M, et al. (2011) Disseminated tumor cells in pancreatic cancer-an independent prognosticator of disease progression and survival. Int J Cancer doi:10.1002/ijc.26439.
40. Wittekind C, Greene FL, Hutter RVP, Klimpfinger M, Sobin LH (2005) TNM atlas: illustrated guide to the TNM/pTNM classification of malignant tumours. 5th ed.
41. Yeatman TJ, Nicolson GL, (1993) Molecular basis of tumor progression: mechanisms of organ-specific tumor metastasis. Semin Surg Oncol 9: 256-263.
42. Bernards R, (2003) Cancer: cues for migration. Nature 425: 247-248.
43. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, et al. (2003) Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425: 307-311.
44. Nakagawa T, Kanai Y, Ushijima S, Kitamura T, Kakizoe T, et al. (2005) DNA hypermethylation on multiple CpG islands associated with increased DNA methyltransferase DNMT1 protein expression during multistage urothelial carcinogenesis. J Urol 173: 1767-1771.
45. Pantel K, Woelfle U, (2005) Detection and molecular characterisation of disseminated tumour cells: implications for anti-cancer therapy. Biochim Biophys Acta 1756: 53-64.
46. Wetzker R, Bohmer FD, (2003) Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol 4: 651-657 10.1038/nrm1173 [doi];nrm1173 [pii].